ICR suckling mouse model of Zika virus infection for disease modeling and drug validation
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 16 of the 23 sources its claims cite were checked for support.
Abstract
BACKGROUND: Zika virus (ZIKV) infection causes diseases ranging from acute self-limiting febrile illness to life-threatening Guillain-Barré Syndrome and other neurological disorders in adults. Cumulative evidence suggests an association between ZIKV infection and microcephaly in newborn infants. Given the host-range restrictions of the virus, a susceptible animal model infected by ZIKV must be developed for evaluation of vaccines and antivirals. In this study, we propose a convenient mouse model for analysis of neurological disorders caused by ZIKV. METHODOLOGY: Six-day-old immunocompetent ICR suckling mice were used in the experiment. Different inoculum virus concentrations, challenge routes, and challenge times were assessed. Viremic dissemination was determined in the liver, spleen, kidney, and brain through Western blot assay, plaque assay, absolute quantification real-time PCR, and histological observation. Azithromycin, a well-characterized anti-ZIKV compound, was used to evaluate the ICR suckling mouse model for antiviral testing. CONCLUSIONS: Signs of illness and neurological disease and high mortality rate were observed in mice injected with ZIKV intracerebrally (102 to 105) and intraperitoneally (103 to 105). Viremic dissemination was observed in the liver, spleen, kidney, and brain. ZIKV transmitted, rapid replicated, and induced monocyte infiltration into the brain approximately 5 to 6 days post inoculum. Azithromycin conferred protection against ZIKV-caused neurological and life-threatening diseases. The developed model of ZIKV infection and disease can be used for screening drugs against ZIKV and discovering the underlying mechanism of ZIKV pathogenesis.
Overview
CoChat Summary
TL;DR
Six-day-old immunocompetent ICR suckling mice support Zika virus (ZIKV) infection by intracerebral and intraperitoneal routes, showing high mortality, systemic viral dissemination, brain monocyte infiltration, and neurological disease. Azithromycin protected against lethal ZIKV infection and reduced brain viral RNA and titer, supporting this model for anti-ZIKV drug testing.
Key findings
- Intracerebral (i.c.) injection of 10²–10⁵ PFU ZIKV caused 80%–100% mortality at 5–7 days post infection (dpi); intraperitoneal (i.p.) injection of 10³–10⁵ PFU caused high mortality about 1 day later, while 10² PFU i.p. led to 20% mortality.
- ZIKV RNA in brain ranged from 10⁹–10¹⁰ copies/μg RNA after i.c. injection and 10⁶–10⁹ copies/μg RNA after i.p. injection; brain viral titer was 10⁷–10⁹ PFU/g tissue (i.c.) versus 10⁴–10⁸ PFU/g tissue (i.p.). ZIKV RNA was also detected in liver (10⁵–10⁸ copies/μg RNA), spleen (10⁴–10⁷), and kidney (10⁵–10⁷).
- Monocyte infiltration into the brain was observed around 5–6 days post inoculum, coinciding with ZIKV detection in brain tissue.
- Azithromycin at 1 and 10 mg/kg protected 80% and 100% of mice, respectively, from life-threatening ZIKV infection; it reduced ZIKV RNA copies by 1.58±0.27 and 2.52±0.25 log10 and viral titer by 0.81±0.18 and 1.55±0.16 log10, respectively, compared with untreated ZIKV-infected mice.
Methods
- Six-day-old ICR suckling mice weighing 3.5–4 g were infected with ZIKV strain MR-766 at 10²–10⁵ PFU by i.c. or i.p. injection; heat-inactivated ZIKV served as mock control. Survival, clinical score, and body weight were recorded daily, with sacrifice at 8 dpi in initial studies.
- Brain, liver, spleen, and kidney tissues were analyzed by Western blot with anti-ZIKV NS2B antibody, absolute quantification real-time PCR targeting ZIKV NS5, plaque assay in Vero cells, H&E staining, and immunohistochemistry with anti-Ly6C antibody quantified by ImageJ.
- For antiviral testing, mice received i.p. 10⁴ PFU ZIKV and azithromycin (1 or 10 mg/kg) at 1, 3, and 5 dpi; controls included heat-inactivated ZIKV and azithromycin-only groups. Data were analyzed by Student’s t-test using GraphPad Prism 6 and expressed as mean ± SD of at least three independent experiments.
Limitations
- The paper states that the age of the suckling mice creates limitations: viremia in the blood was hard to collect and process, and studies of vertical transmission were not available.
- Evident from the text: experimental groups used small sample sizes (n = 3–5), observation periods were short (7–8 dpi), and only ZIKV strain MR-766 was tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
7 Valid · 2 Not valid · 3 Not checked · 43 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In this regard, small animal models are a better choice for studying ZIKV [10, 21].”
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Introduction
What the sources say
- Supportedcites [10] SD Dowall, 2016, A Susceptible Mouse Model for Zika Virus Infection, PLoS neglected tropical diseases source
The Introduction says a small-animal disease model would advance ZIKV research and enable a wider range of studies. The Discussion identifies the authors’ adult mouse model as suitable and informative, particularly for testing vaccines and therapeutics. The paper supports the broad preference expressed in the citing sentence, though its demonstrated model is specifically A129 mice. (LLM, conf=0.86)
- Supportedcites [21] MT Aliota, 2016, Characterization of Lethal Zika Virus Infection in AG129 Mice, PLoS neglected tropical diseases source
The Introduction says that establishing a small-animal model is important for understanding ZIKV pathogenesis and immunity. It explains that nonhuman primate models are prohibitively expensive for such studies, motivating the development of a mouse model. The paper presents this as a practical advantage, not a claim that mice are preferable for every ZIKV research question. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Furthermore, AG129 and Irf3/5/7 TKO mice has been indicated to be uncommonly available in some research laboratories [33, 34].”
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Discussion
What the sources say
- Not checked — no full text of the sourcecites [33] SS Pawitwar, 2017, Overview on the Current Status of Zika Virus Pathogenesis and Animal Related Research, Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology source
- Could not verifycites [34] HM Lazear, 2016, A Mouse Model of Zika Virus Pathogenesis, Cell host & microbe sourceExperimental — accuracy not yet measured
The Experimental Procedures (Mouse experiments; page not provided) list AG129 and Irf3/5/7 TKO mice among the strains used and say the mice were bred at Washington University or, for WT and CD-1 mice, purchased. Neither that passage nor the Results passages address how commonly these strains are available in other research laboratories. Searched for availability and whether the strains are widely available. (LLM, conf=0.76)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“injection of 10 mg/kg Az decreased the ZIKV RNA copies and viral titer by 2.52±0.25 and 1.55±0.16, respectively, compared with that in ZIKV-infected mice that were not treated with Az”
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Result > Azithromycin prevented ZIKV-induced lethality and inhibited ZIKV replication in the suckling mouse model
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“monocyte infiltration was observed at approximately the same time when ZIKV was detected in the brain tissue.”
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Result > ZIKV invaded brain tissue of ICR suckling mice
plainstates an associationn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the i.c. injection caused death approximately 1 day earlier than the i.p. injection.”
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Result > ZIKV caused lethality in the suckling mouse model
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 55 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 8
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Materials and methods > Evaluation of anti-ZIKV replication activity assay in ICR suckling mouse model
“Six-day-old ICR suckling mice weighing 3.5–4 g were randomly divided into four groups:”
§ ICR suckling mouse model of Zika virus infection for disease modeling and drug validation > Materials and methods > Evaluation of anti-ZIKV replication activity assay in ICR suckling mouse model
“group 1: i.p. injectedwith 104 PFU heat-inactivated ZIKV (iZIKV); group 2 received 10 mg/kg of Az but without ZIKV infection (Az 10 mg/kg); group 3: i.p. injected with 104 PFU ZIKV and saline (ZIKV); group 4: i.p. injected with 104 PFU ZIKV and 1 mg/kg Az (ZIKV+Az 1mg/kg); and group 5: i.p. injected with 104 PFU ZIKV virus and 10mg/kg Az (ZIKV+Az 10mg/kg).”
Citations
Cites
Zika Virus Outbreak on Yap Island, Federated States of Micronesia
Duffy, M. R., Chen, T.-H., Hancock, W. T., Powers, A. M., Kool, J. L., Lanciotti, R. S., Pretrick, M., Marfel, M., Holzbauer, S., Dubray, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805715 · Cited by 3,132
Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00562-6 · Cited by 2,205
Musso, D., & Gubler, D. J. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-15 · Cited by 1,469
Petersen, L. R., Jamieson, D. J., Powers, A. M., & Honein, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1602113 · Cited by 1,173
A Mouse Model of Zika Virus Pathogenesis
Lazear, H. M., Govero, J., Smith, A. M., Platt, D. J., Fernandez, E., Miner, J. J., & Diamond, M. S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.03.010 · Cited by 909
Zika Virus, French Polynesia, South Pacific, 2013
Cao-Lormeau, V.-M., Roche, C., Teissier, A., Robin, E., Berry, A.-L., Mallet, H.-P., Sall, A. A., & Musso, D. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2006.140138 · Cited by 874
Molecular Evolution of Zika Virus during Its Emergence in the 20th Century
Faye, O., Freire, C. C. M., Iamarino, A., Faye, O., de Oliveira, J. V. C., Diallo, M., Zanotto, P. M. A., & Sall, A. A. (2014) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002636 · Cited by 819
Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice
Li, C., Xu, D., Ye, Q., Hong, S., Jiang, Y., Liu, X., Zhang, N., Shi, L., Qin, C.-F., & Xu, Z. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.017 · Cited by 749
Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses
Kuno, G., & Chang, G.-J. J. (2007) · Archives of Virology · doi:10.1007/s00705-006-0903-z · Cited by 539
Zika virus cell tropism in the developing human brain and inhibition by azithromycin
Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., Mancia Leon, W. R., Krencik, R., Ullian, E. M., Spatazza, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618029113 · Cited by 506
Cited by
Azithromycin: The First Broad-spectrum Therapeutic
Firth, A. E. J., & Prathapan, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112739 · Cited by 163
Azithromycin for COVID-19: More Than Just an Antimicrobial?
Bleyzac, N., Goutelle, S., Bourguignon, L., & Tod, M. M. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00933-3 · Cited by 133
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 96
“Tumor bearing animals were scored from 0 to 5 based on the 350 following scale: 0, no disease; 1, ruffled fur, piloerection, weight loss or slow movements; 2, 351 lethargy, unsteady gait or hunched back; 3, decreased strength in either fore and/or hind limbs; 352 4, restricted movement, extreme body weight loss (over…”
BackgroundProtective to a T: The Role of T Cells during Zika Virus Infection
Pardy, R. D., & Richer, M. J. (2019) · Cells · doi:10.3390/cells8080820 · Cited by 47
Trus, I., Udenze, D., Berube, N., Wheler, C. L., Martel, M.-J., Gerdts, V., & Karniychuk, U. U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03077 · Cited by 48
“Histopathology and Immunohistochemistry Mouse brain tissues were dissected and fixed in formalin for subsequent H&E staining to screen lesions (45, 46).”
MethodResultLate Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches
Souza, I. N. D. O., Barros‐Aragão, F. G. Q., Frost, P. S., Figueiredo, C. P., & Clarke, J. R. (2019) · Pharmaceuticals · doi:10.3390/ph12020060 · Cited by 40
“)-treated mice showed decreased mortality, better clinical score, fewer viral RNA copies in the brain and reduced monocyte infiltration following ZIKV infection [83].”
BackgroundErythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator
Wang, X., Xia, S., Zou, P., & Lu, L. (2019) · Viruses · doi:10.3390/v11111064 · Cited by 26
“As the effective macrolides with diverse characteristics and advantages are constantly discovered [19] [20] [21] [22] [23] 46] , more opportunities for research and clinical treatment can be provided.”
BackgroundMethodKomarasamy, T. V., Adnan, N. A. A., James, W., & Balasubramaniam, V. R. M. T. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010291 · Cited by 27
McDonald, E., Anderson, J., Wilusz, J., Ebel, G. D., & Brault, A. C. (2020) · Journal of Virology · doi:10.1128/jvi.00838-20 · Cited by 23
Update on the Animal Models and Underlying Mechanisms for ZIKV-Induced Microcephaly
Xu, D., Li, C., Qin, C., & Xu, Z. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015740 · Cited by 22
Cochin, M., Touret, F., Driouich, J., Moureau, G., Petit, P.-R., Laprie, C., Solas, C., de Lamballerie, X. N., & Nougaırède, A. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105212 · Cited by 16
“antiviral activity in cell culture and some studies reported its efficacy against several RNA viruses infections using ex vivo and preclinical models (Madrid et al., 2015; Menzel et al., 2016; Schögler et al., 2015; Wu et al., 2018; Zeng et al., 2019).”
Abdulaziz, L., Elhadi, E., Abdallah, E. A., Alnoor, F. A., & Yousef, B. A. (2022) · Journal of Experimental Pharmacology · doi:10.2147/jep.s346006 · Cited by 17
Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication
Lin, W., Huang, Y.-J., Wang, Y., Lin, Y.-S., Mazibuko, N., Chen, C., Cheng, T., Chang, C., Leu, Y.-L., Chen, C., et al. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199092 · Cited by 14
Yellow fever vaccine protects mice against Zika virus infection
Santos, A. C. V., Guedes-da-Silva, F. H., Dumard, C. H., Ferreira, V. N. D. S., da Costa, I. P. S., Machado, R. A., Barros‐Aragão, F. G. Q., Neris, R. L. S., dos-Santos, J. S., Assunção‐Miranda, I., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009907 · Cited by 13
“An IC infection in which ZIKV is inoculated directly into the CNS has a highly neurovirulent and pathogenic route; this route is considered a severe model of infection [18] and may require a strong immune response, which can probably be achieved only by using live vaccines, to protect the brain.”
BackgroundLive Viral Vaccine Neurovirulence Screening: Current and Future Models
Fulton, C. M., & Bailey, W. J. (2021) · Vaccines · doi:10.3390/vaccines9070710 · Cited by 10
Kitaura, S., Tobiume, M., Kawahara, M., Satoh, M., Kato, H., Nakayama, N., Nakajima, N., Komeno, T., Furuta, Y., Suzuki, T., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105582 · Cited by 10
Abdulaziz, L., Elhadi, E., Abdallah, E. A., et al. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 8
Udenze, D., Trus, I., Berube, N., & Karniychuk, U. U. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943481 · Cited by 9
“Mice in wild-type and E/NS1+176CpG groups had brain histopathology represented by cell infiltration in the hippocampus and blood vessel inflammation (Figures 2B, D) consistent with previously described histopathology in Zika virus-infected mouse brains (10, 33, 34).”
ResultDeveloping animal models of Zika virus infection for novel drug discovery
Ohki, C. M. Y., Benazzato, C., Russo, F. B., & Beltrão-Braga, P. C. B. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1597050 · Cited by 10
“Azithromycin, an antibiotic used against pneumonia, gastrointestinal and sexually transmitted infections, administered in conjunction with another drug against malaria infection, were tested in ICR suckling mice, decreasing viremia and infiltration of monocytes into the CNS, ameliorating clinical signs of infection an…”
BackgroundSchmitt, K. P., Curlin, J., Remling‐Mulder, L., Aboellail, T., & Akkina, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1060959 · Cited by 10
Rengifo, A. C., Rivera, J., Álvarez-Díaz, D. A., Naizaque, J., Santamaría, G., Corchuelo, S., Gómez, C. Y., & Torres‐Fernández, O. (2023) · Viruses · doi:10.3390/v15081632 · Cited by 8
“2018, after inoculating immunocompetent infant mice with an African strain (MR-766) of ZIKV and a viral dose similar to that reported by us, showed the onset of clinical signs between the second and fifth dpi, and severe paralysis or death on the second or third day after the onset of clinical signs [80].”
BackgroundHelal, M. G., Shawky, M., Elhusseiny, S. H., & Elhameed, A. G. A. (2021) · Journal of Advanced Pharmacy Research · doi:10.21608/aprh.2021.62735.1122 · Cited by 11
Modeling Human Viral Diseases: Trials and Triumphs
Ayyavoo, V. (2021) · Frontiers in Virology · doi:10.3389/fviro.2021.722297 · Cited by 5
WITHDRAWN: Azithromycin: The First Broad-spectrum Therapeutic
Kruger, D., & Prathapan, P. (2020) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2020.100062 · Cited by 5
RetractedWu, Y., Chen, W., Tseng, C., Chen, Y., Lin, C., & Lee, J. (2021) · The FASEB Journal · doi:10.1096/fj.202100688rrr · Cited by 11
Self-citationAssessment of drugs administered in the Middle East as part of the COVID-19 management protocols
Elekhnawy, E., Negm, W. A., El-Sherbeni, S. A., & Zayed, A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01050-7 · Cited by 5
Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus InfectionPreprint
Santos, A. C. V., Guedes-da-Silva, F. H., Dumard, C. H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/587444 · Cited by 4
Sethiya, J. P., & Wagner, C. R. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00709 · Cited by 6
African lineage 1a West Nile virus isolated from crocodiles exhibits low neuroinvasiveness in mice
Kobayashi, H., Chambaro, H. M., Tabata, K., et al. (2024) · Journal of General Virology · doi:10.1099/jgv.0.002051 · Cited by 1
Modelos animais para infecção experimental pelo vírus Zika: uma revisão sistemática
Bandeira, D. M., de Almeida, A. L. T., Caldas, G. C., & Barreto-Vieira, D. F. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e13209.2023 · Cited by 1
Padayachee, N., M., M., & Schellack, N. (2021) · South African General Practitioner · doi:10.36303/sagp.2021.2.1.0059 · Cited by 2
Nonhuman occurrence of Zika virus infection: Implications for control
Beck, C., Hamel, R., Dumarest, M., Gonzalez, G., & Lecollinet, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820268-5.00042-0 · Cited by 1
ПРИМЕНЕНИЕ ПЛЕОТРОПНЫХ ЭФФЕКТОВ АНТИБИОТИКОВ ПРИ ЛЕЧЕНИИ SARS-COV-2
Александр, Е. Г., Зарина, Т. Ш., Татьяна, Н. К., Жаныбек, Т. Б., & Ерлан, М. Р. (2023) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2023.51.32.017
БАКТЕРИЯҒА ҚАРСЫ ЗАТТАРДЫҢ ПЛЕЙОТРАПТЫ ӘСЕРЛЕРІ (ШОЛУ)
Ахмадьяр, А. Н., С., Б. С., Сүлейменова, Е. Д., & Аубакирова, Ж. Т. (2024) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2024.33.42.026
Kan, J.-Y., Su, H.-C., Lai, H., Lin, Y., Chiu, S., Wu, P.-C., Hsueh, P., Lu, C., & Lin, C. (2026) · Journal of Medical Virology · doi:10.1002/jmv.71092
Self-citation
Metadata
- Authors
- Wu, Y.-H., Tseng, C.-K., Lin, C.-K., Wei, C.-K., Lee, J.-C., & Young, K.-C.
- Affiliations
- National Cheng Kung University (TW)
- National Sun Yat-sen University (TW)
- Kaohsiung Medical University (TW)
- Corresponding author
- Lee, Jin-Ching
- Young, Kung-Chia
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-10-24
- Volume
- 12
- Issue
- 10
- Pages
- e0006848
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- PMC
- PMC6218097
- OpenAlex
- W2898365945
- Semantic Scholar
- 77de253428189d85970e4254e42ecf17c525cd5f
- Cited by
- 35
- References
- 54
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 6
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Update notices
- new_version (2018-11-05)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS neglected tropical diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Science and Technology, Taiwan ((MOST104-2320-B-037-025-MY3, MOST 107-2311-B-037 -005 -MY3)
- Kaohsiung Medical University (KMU-DK107011)
- National Sun Yat-sen University (NSYSU-KMU 107-I003)
- Industry-University Service Research Project (S106002)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Mosquito-borne diseases and control
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Vectors
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
- Keywords
- Zika virus, suckling mouse model, neurological disorders, Guillain-Barré syndrome, microcephaly, viremia, azithromycin, antiviral drug screening, vaccine evaluation, viral pathogenesis, intracerebral injection, intraperitoneal inoculation
- MeSH terms
- Zika Virus Infection, Zika Virus, Animals, Animal Structures, Animals, Newborn, Antiviral Agents, Disease Models, Animal, Drug Evaluation, Preclinical, Histocytochemistry, Mice, Inbred ICR, Viral Plaque Assay, Viral Load, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.